Journal of Pharmacogenomics & Pharmacoproteomics

Potential Benefits of Genomics and Proteomics to Manage Cardiovascular Risk in Autoimmune Diseases

Patrinos Rami^* Department of Pharmacology and Toxicology, American University of Beirut, Beirut, Lebanon
^*Correspondence: Patrinos Rami, Department of Pharmacology and Toxicology, American University of Beirut, Beirut, Lebanon, Email:

Received: 03-Jul-2023, Manuscript No. JPP-23-22441 ; Editor assigned: 07-Jul-2023, Pre QC No. JPP-23-22441 (PQ); Reviewed: 21-Jul-2023, QC No. JPP-23-22441 ; Revised: 28-Jul-2023, Manuscript No. JPP-23-22441 (R); Published: 04-Aug-2023, DOI: 10.35248/2153-0645.23.14.065

Description

Genomics and proteomics are used to help identify individual risk factors that could lead to cardiovascular disease in individuals who have been diagnosed with an autoimmune disorder. Genomics refers to studying the human genome in order to uncover genetic variations that may contribute to the development of cardiovascular disease [1]. Proteomics focuses on analyzing proteins found in the blood in order to determine if they could be associated with poor cardiovascular health. These tools allow medical professionals the ability to identify a patient’s personal risk factors and put strategies in place that can help minimize their chances of developing cardiovascular problems [2].

In addition, both genomics and proteomics are used in research studies related to cardiac care and autoimmune disorders. For example, researchers have recently begun exploring the use of genomics and proteomics as biomarkers for predicting future cardiovascular events in those with autoimmune diseases. This has allowed medical professionals more insight into which treatments may be most beneficial for individual patients [3]. Genomics and proteomics provide invaluable tools for understanding how different genetic factors interact with each other and how this may affect overall health outcomes.

Recent advances in the field of genomics and proteomics have opened up new possibilities for the understanding and management of cardiovascular risks associated with autoimmune diseases. Genomics is the study of the entire genome, in particular its structure, function, and variations. Proteomics is the study of protein expression patterns in a cell, tissue or organism [4]. Significant tools for understanding how genetic factors may be involved in autoimmune diseases and how they can affect cardiovascular health. Recent studies have shown that genetic variants may play a role in both autoimmune diseases such as rheumatoid arthritis and Systemic Lupus Erythematosus (SLE) as well as cardiovascular diseases like coronary artery disease, stroke, hypertensive heart disease, and atrial fibrillation [5]. In addition to genetics, research has also revealed links between inflammation-related proteins such as cytokines and chemokines which are involved in immune system functioning, and cardiovascular risk factors such as high cholesterol levels or poor blood sugar control.

Autoimmune diseases occur when the immune system mistakenly attacks healthy tissue. These diseases can cause significant damage to the body, including to the cardiovascular system. To better understand and manage cardiovascular risk associated with autoimmune diseases, scientists are exploring genomics and proteomics in order to identify and monitor risk factors [6]. Genomics is the study of all of an organism’s genes that are responsible for specific traits or characteristics. By analyzing a person’s genome, it is possible to gain insight into their medical history, predict potential health risks, and devise tailored treatments for their condition. Similarly, proteomics is a branch of molecular biology that looks at the structure, function, and interaction of proteins in a cell [7]. Proteins are responsible for many vital functions in the body. By studying these molecules, researchers can gain further insight into how autoimmune diseases affect cardiovascular health. Both genomics and proteomics have been found to be useful for understanding how certain genes or proteins may influence autoimmune disease activity and cardiovascular risk factors. This data can be used to develop diagnostic tools or treatments that can improve patient outcomes by reducing incidence or severity of disease-related complications such as heart disease or stroke [8]. As scientists continue to explore this area further, it may soon be possible to use genetic markers predict which individuals are at higher risk for developing these conditions.

Autoimmune diseases occur when the body’s immune system mistakenly attacks healthy tissue, leading to an inflammatory response. In some cases, this can result in increased cardiovascular risk due to inflammation that affects the heart and blood vessels. Fortunately, by using genomics and proteomics, it is possible to better understand the genetic factors that contribute to autoimmune diseases and analyze proteins associated with inflammation [9]. The use of genomics has enabled researchers to identify genes associated with an increased risk for developing autoimmune diseases and their potential consequences. Proteomics is also a powerful tool for understanding inflammation-related cardiovascular risks in people with autoimmune diseases. Proteins are essential molecules involved in numerous physiological processes, including inflammation, and by analyzing these molecules it is possible to better understand how they may be contributing to increased cardiovascular risk. By combining the power of genomics and proteomics, it is possible to gain insights into how particular genetic variants or proteins may be influencing an individual’s cardiovascular risks due to autoimmunity [10]. This knowledge may enable medical professionals to recommend tailored treatments or lifestyle modifications that could reduce the risks associated with these conditions.

References

1. Zhou Y, Tremmel R, Schaeffeler E, Schwab M, Lauschke VM. Challenges and opportunities associated with rare-variant pharmacogenomics. Trends Pharmacol Sci. 2022; 43:852-865.

   [Crossref] [Google Scholar] [PubMed]

2. Kasuga T, Taylor JW, White TJ. Phylogenetic relationships of varieties and geographical groups of the human pathogenic fungus histoplasma capsulatum darling. J Clin Microbiol.1999;37:653-663.

   [Crossref] [Google Scholar] [PubMed]

3. Keeling NJ, Dunn TJ, Bentley JP, Ramachandran S, Hoffman JM, Rosenthal M. Approaches to assessing the provider experience with clinical pharmacogenomics information: a scoping review. Genet Med. 2021; 23:1589-1603.

   [Crossref] [Google Scholar] [PubMed]

4. Liu D, Olson KL, Manzi SF, Mandl KD. Patients dispensed medications with actionable pharmacogenomics biomarkers: rates and characteristics. Genet Med. 2021; 23:782-786.

   [Crossref] [Google Scholar] [PubMed]

5. Murata Y, Sano A, Ueda Y, Inomata T, Takayama A, Poonwan N, et al. Molecular epidemiology of canine histoplasmosis in Japan. Sabouraudia. 2007;45(3):233-247.

   [Crossref] [Google Scholar] [PubMed]

6. Habich C, Kempe K, Gomez FJ, Lillicrap M, Gaston H, van der Zee R, et al. Heat shock protein 60: identification of specific epitopes for binding to primary macrophages. FEBS letters. 2006;580(1):115-120.

   [Crossref] [Google Scholar] [PubMed]

7. Ajello L. Comparative morphology and immunology of members of the genus histoplasma: A review. Mycoses. 1968;11(7):507-514.

   [Crossref] [Google Scholar] [PubMed]

8. Chandler FW, Kaplan W, Ajello L. Histoplasmosis duboisii. A Colour Atlas and Textbook of the Histopathology of Mycotic Diseases. Wolfe Medical Publications.1980:67-69.

   [Crossref] [Google Scholar]

9. Keeling NJ, Dunn TJ, Bentley JP, Ramachandran S, Hoffman JM, Rosenthal M. Approaches to assessing the provider experience with clinical pharmacogenomics information: a scoping review. Genet Med. 2021; 23:1589-1603.

   [Crossref] [Google Scholar] [PubMed]

10. Liu D, Olson KL, Manzi SF, Mandl KD. Patients dispensed medications with actionable pharmacogenomics biomarkers: rates and characteristics. Genet Med. 2021; 23:782-786.

    [Crossref] [Google Scholar] [PubMed]